Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has been given a consensus rating of “Moderate Buy” by the eighteen analysts that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and three have issued a strong buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $110.9091.

GPCR has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Citizens Jmp lowered their price objective on shares of Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating for the company in a research note on Friday, August 7th. Wall Street Zen lowered shares of Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday. Canaccord Genuity Group set a $111.00 price objective on shares of Structure Therapeutics in a report on Friday. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday.

Structure Therapeutics Stock Performance

Structure Therapeutics stock opened at $52.13 on Friday. The company has a market capitalization of $3.70 billion, a PE ratio of -52.13 and a beta of -1.43. Structure Therapeutics has a fifty-two week low of $17.52 and a fifty-two week high of $94.90. The firm has a 50 day moving average price of $48.24 and a 200 day moving average price of $53.39.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, equities research analysts forecast that Structure Therapeutics will post -1.78 earnings per share for the current year.

Institutional Trading of Structure Therapeutics

Hedge funds have recently modified their holdings of the stock. Handelsbanken Fonder AB purchased a new stake in Structure Therapeutics during the 2nd quarter worth about $1,041,000. Seven Fleet Capital Management LP purchased a new position in shares of Structure Therapeutics in the 1st quarter valued at about $434,000. Avidity Partners Management LP acquired a new position in shares of Structure Therapeutics during the first quarter worth about $1,446,000. Bank of America Corp DE grew its position in shares of Structure Therapeutics by 617.0% during the first quarter. Bank of America Corp DE now owns 227,132 shares of the company’s stock worth $10,948,000 after buying an additional 195,454 shares in the last quarter. Finally, Janus Henderson Group PLC increased its stake in shares of Structure Therapeutics by 5.2% during the first quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock worth $258,260,000 after buying an additional 264,833 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.